The United Kingdom and the United States have reached a landmark bilateral deal that will guarantee zero tariffs on UK medicine exports going into the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to raise expenditure on medicines through the public health system. This pledge secures that import taxes on these key exports will be held at zero for a timeframe of three years.
This development is in response to earlier threats to dramatically increase duties on patented pharmaceutical products, with potential rates mentioned up to double the cost.
"This arrangement with the UK reinforces the global environment for cutting-edge drugs and introduces long-overdue balance to transatlantic medicine commerce," a release declared.
Trade Importance
Medicines are one of the the United Kingdom's most significant exports to the US, which is clearly the largest market for large companies like GSK and AstraZeneca.
Trade data show that in the 12 months leading up to September, the UK sold medicines totaling over eleven billion pounds to the US. This amount accounted for nearly one-fifth of British export trade in that timeframe.
"This guarantee safeguards work, boosts funding and paves the way for the UK to emerge as a global hub for biotech and pharma," a government official remarked.
Key UK Commitments
The pact includes several notable commitments from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase total NHS spending on medicines from 0.3% of GDP to 0.6% over the next decade.
- Payback Limit: The amount drug companies must return to the NHS to control costs will be limited at fifteen percent. Last year, rebates exceeded 20%.
Recent Tensions
This agreement follows a ongoing row between the sector and the UK government over drug pricing and NHS adoption.
The disagreement were exacerbated by assertions that American consumers were paying several times more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several major drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been directed toward US facilities.
One official publicly accepted that the NHS had to spend more on drugs, noting that its spending on drugs had declined as a share of its overall budget over the last ten years.
